^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ARSI overexpression

    i
    Other names: ARSI, Arylsulfatase Family Member I, Arylsulfatase I, SPG66, FLJ16069, ASI, Arylsulfatase Family, Member I
    Entrez ID:
    340075
    11ms
    SOX expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis. (PubMed, Cancer Lett)
    Importantly, pharmacological targeting of WEE1 (WEE1i) in combination with an ARSI or GR modulator re-sensitizes SOX2-positive PC cells to nuclear hormone receptor signaling inhibition in vitro, and WEE1i combined with ARSI significantly slowed tumor growth in vivo. Collectively, our data suggest SOX2 predicts NHRSI resistance, and simultaneously indicates the addition of WEE1i to improve therapeutic efficacy of NHRSIs in SOX2-positive PC.
    Journal
    |
    SOX2 • ARSI (Arylsulfatase Family Member I) • CDK1 (Cyclin-dependent kinase 1) • NR3C1 (Nuclear Receptor Subfamily 3 Group C Member 1)
    |
    ARSI overexpression • SOX2 expression